Bharat Biotech Concludes Final Analysis for COVAXIN Efficacy from Phase 3 Clinical Trials
- Efficacy analysis demonstrates COVAXIN to be 77.8% effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group - Efficacy analysis demonstrates COVAXIN to be 93.4% effective against severe symptomatic COVID-19 - Safety analysis demonstrates adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events - Efficacy data demonstrates 63.6% protection against asymptomatic COVID-19 - Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant
